1611PDA phase II, multicenter study of the EZH2 inhibitor tazemetostat in adults (INI1-negative tumors cohort) (NCT02601950). (23rd October 2018) - Stacchiotti, S; Blay, J-Y; Jones, R L; Demetri, G D D; Mir, O; Italiano, A; Thomas, D; Chen, T W-W; Schöffski, P; Gil, T; Jahan, T; Cote, G; et al.